Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030051014> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W3030051014 endingPage "1017" @default.
- W3030051014 startingPage "1014" @default.
- W3030051014 abstract "ObjectiveTo explore the effect of ziprasidone combined with low dose of olanzapine in the treatment of schizophrenia with depressive symptoms, and its lipid metabolism.MethodsAccording to the digital table,108 schizophrenia patients with depressive symptoms were randomly divided into the two groups. The treatment group(n= 54)was given starting doses of ziprasidone with 2.5mg/d, increased to 5- 10 mg/d for 1 week. And starting doses of olanzapine with 40mg/d,increased to 120- 160mg/d for 2 weeks.The control group(n= 54) was given starting doses of olanzapine with 5mg/d,increased to 10- 20mg/d for 2 weeks.The treatment course was 8 weeks. The PANSS score and HAMD score, indicators of obesity and blood lipid and adverse effect were observed.ResultsThe PANSS score and HAMD score in the treatment group[(40.19±9.23) vs(59.29±10.14)]and the control group[(8.58±3.16) vs(12.19±4.04)]were significantly lower than those before treatment(t= 9.41,4.91,6.51,5.20,all P< 0.05), and the scores in the treatment group were reduced more remarkably(t= 5.11,3.01,all P<0.05). The waistline(83.45±5.29)cm,BMI(26.95±2.53)kg/m2,WHR(23.76 ±2.55)cm in the control group were all increased compared with those before treatment(t= 5.14,3.18,all P< 0.05) while the indicators[(23.76±2.55) vs(23.76±2.55)]above improved more remarkably in the treatment group than those in the control group(t= 5.38,4.53,all P< 0.05).Compared with before treatment,the level of TC(6.54±0.86)mmol/L,TG(2.26±0.83)mmol/L,LDL- C(3.94±0.43)mmol/L were increased remarkably, and HDL- C(1.02±0.18)mmol/L was reduced in the control group,TC(5.35±0.58)mmol/L in treatment group in the treatment group(t= 4.20,3.27,3.91,2.97,4.47,all P< 0.05),while the indicators of blood lipid in the treatment group were better than those in the control group(t= 3.18,3.01,2.76,2.87,all P< 0.05). The TESS score in the treatment group(3.35±0.57)point was lower than that in the control group(4.93± 1.03)point(t= 3.98,P<0.05).ConclusionIt is effective and safe of combined with low dose of olanzapine in the treatment of schizophrenia with depressive symptoms, which can contribute to effectively alleviate symptoms of depression with low effect on body weight and blood lipid metabolism, less adverse reaction.Key words: Schizophrenia; Depressive symptoms; Ziprasidone; Olanzapine; Lipid metabolism" @default.
- W3030051014 created "2020-06-05" @default.
- W3030051014 creator A5035642317 @default.
- W3030051014 date "2015-04-01" @default.
- W3030051014 modified "2023-09-25" @default.
- W3030051014 title "Effect and influence on lipid metabolism of ziprasidone combined with low dose of olanzapine in the treatment of schizophrenia with depressive symptoms" @default.
- W3030051014 doi "https://doi.org/10.3760/cma.j.issn.1008-6706.2015.07.018" @default.
- W3030051014 hasPublicationYear "2015" @default.
- W3030051014 type Work @default.
- W3030051014 sameAs 3030051014 @default.
- W3030051014 citedByCount "0" @default.
- W3030051014 crossrefType "journal-article" @default.
- W3030051014 hasAuthorship W3030051014A5035642317 @default.
- W3030051014 hasConcept C118552586 @default.
- W3030051014 hasConcept C126322002 @default.
- W3030051014 hasConcept C197934379 @default.
- W3030051014 hasConcept C2776412080 @default.
- W3030051014 hasConcept C2776619155 @default.
- W3030051014 hasConcept C2777198177 @default.
- W3030051014 hasConcept C2777270317 @default.
- W3030051014 hasConcept C3018023364 @default.
- W3030051014 hasConcept C71924100 @default.
- W3030051014 hasConcept C90924648 @default.
- W3030051014 hasConceptScore W3030051014C118552586 @default.
- W3030051014 hasConceptScore W3030051014C126322002 @default.
- W3030051014 hasConceptScore W3030051014C197934379 @default.
- W3030051014 hasConceptScore W3030051014C2776412080 @default.
- W3030051014 hasConceptScore W3030051014C2776619155 @default.
- W3030051014 hasConceptScore W3030051014C2777198177 @default.
- W3030051014 hasConceptScore W3030051014C2777270317 @default.
- W3030051014 hasConceptScore W3030051014C3018023364 @default.
- W3030051014 hasConceptScore W3030051014C71924100 @default.
- W3030051014 hasConceptScore W3030051014C90924648 @default.
- W3030051014 hasIssue "07" @default.
- W3030051014 hasLocation W30300510141 @default.
- W3030051014 hasOpenAccess W3030051014 @default.
- W3030051014 hasPrimaryLocation W30300510141 @default.
- W3030051014 hasRelatedWork W2354160065 @default.
- W3030051014 hasRelatedWork W2356025818 @default.
- W3030051014 hasRelatedWork W2356103087 @default.
- W3030051014 hasRelatedWork W2362920832 @default.
- W3030051014 hasRelatedWork W2363226878 @default.
- W3030051014 hasRelatedWork W2364104386 @default.
- W3030051014 hasRelatedWork W2366766430 @default.
- W3030051014 hasRelatedWork W2367235759 @default.
- W3030051014 hasRelatedWork W2368015335 @default.
- W3030051014 hasRelatedWork W2370748529 @default.
- W3030051014 hasRelatedWork W2373966068 @default.
- W3030051014 hasRelatedWork W2374123646 @default.
- W3030051014 hasRelatedWork W2382111575 @default.
- W3030051014 hasRelatedWork W2384116238 @default.
- W3030051014 hasRelatedWork W2387898339 @default.
- W3030051014 hasRelatedWork W2388280831 @default.
- W3030051014 hasRelatedWork W2389889654 @default.
- W3030051014 hasRelatedWork W3029118673 @default.
- W3030051014 hasRelatedWork W3031262660 @default.
- W3030051014 hasRelatedWork W3199512760 @default.
- W3030051014 hasVolume "22" @default.
- W3030051014 isParatext "false" @default.
- W3030051014 isRetracted "false" @default.
- W3030051014 magId "3030051014" @default.
- W3030051014 workType "article" @default.